Evolent Health, Inc. (EVH) - Form 8-K Summary
Business Context and Reporting Period
Date: November 17, 2022
Company: Evolent Health, Inc.
Event: Entry into a Material Definitive Agreement to acquire the Specialty Health Division of Magellan Health, Inc. (including National Imaging Associates, Inc.).
Key Financial Metrics and Transaction Structure
This filing details a strategic acquisition rather than periodic financial results. Key transaction metrics include:
- Total Transaction Consideration: $650,000,000 (subject to working capital, cash, and debt adjustments).
- Payment Structure:
- Cash: $400,000,000 (implied, as $250M is equity).
- Equity: $250,000,000 via issuance of 8,474,576 Class A Common Shares at $29.50/share.
- Earnout Consideration: Up to $150,000,000 contingent on 2023 operating results, payable in cash and/or Class A Shares.
- Financing Commitments:
- Debt: $265,000,000 total from Ares Capital ($25M ABL Incremental + $240M Term Loan Incremental).
- Equity: $175,000,000 in Convertible Preferred Stock from Ares (initial liquidation preference).
- Termination Fee: $52,000,000 payable by Evolent to Magellan under specific breach or failure to close scenarios.
Material Changes and Financing Terms
The filing outlines significant changes to the company's capital structure and debt obligations to fund the acquisition:
- Debt Terms:
- Term Loan Incremental: Adjusted Term SOFR + 6.00% or Base Rate + 5.00%.
- ABL Incremental: Adjusted Term SOFR + 4.00% or Base Rate + 3.00%.
- Maturity: Earliest of 6 years from Amendment No. 1 effective date or 91 days prior to Junior Debt maturity.
- Preferred Stock Terms:
- Dividend Rate: Adjusted Term SOFR + 6.00% (with a 1.00% floor on SOFR), payable quarterly in cash.
- Conversion Price: $40.00 per share (subject to anti-dilution).
- Redemption: Company may redeem after 2 years; mandatory redemption at 150% of liquidation preference after 7 years or upon change of control.
- Lock-Up: Magellan Entities restricted from selling Class A Shares for 15 months post-closing (with partial releases at 9 and 12 months).
Outlook, Risks, and Contingencies
Closing Conditions: The transaction is subject to customary conditions, including HSR Act waiting period expiration, absence of legal impediments, and accuracy of representations. Closing is expected within three business days of condition satisfaction.
Termination Risks: The agreement may be terminated if closing does not occur by August 17, 2023 (extendable to November 17, 2023 if only HSR remains). Termination by Magellan due to Evolent breach triggers a $52M fee.
Forward-Looking Statements: The company disclaims obligations to update forward-looking statements regarding the consummation of the deal, noting risks of delay or failure to close.
Investor Verification Checklist
- Verify the final purchase price adjustments related to net working capital, cash, and indebtedness at closing.
- Confirm the status of the HSR Act waiting period and any regulatory approvals required.
- Review the specific operating metrics required to trigger the $150M earnout payment.
- Assess the impact of the new $265M debt and $175M preferred stock on the company's pro forma leverage ratios and liquidity.
- Monitor the 15-month lock-up period for Magellan's equity stake and potential market impact upon release.